Primary antiphospholipid syndrome – a retrospective study of 29 patients followed in an Autoimmune Disease Unit

• Autor(a) principal: Costa, Cláudia
• Data de Publicação: 2009
• Outros Autores: Castanheira, Rui, Coelho, Fátima, Dias, Carlos
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://revista.spmi.pt/index.php/rpmi/article/view/1376
• topic: síndrome antifosfolípida; anticardiolipina; auto-anticorpos; anticoagolante lúpico; antiphospholipid syndrome; anticardiolipin; lupus anticoagulant; autoantibodies

The authors present a retrospective study of twenty-nine patients with primary antiphospholipid syndrome, 22 females and seven male patients. Mean cohort age was 34.4 years (20-57 years). Mean age of onset was 30.7 (20-53 years). The serological findings were anticardiolipin antibodies positive in 27 patients (93%), anti-ß2-glicopretein 1 antibodies in 25 (86%) and lupus anticoagulant in 22 (76%). The main manifestations included acute myocardial infarction in two patients, pulmonary thromboembolism in two, one patient with mesenteric thrombosis, one with venous sinus thrombosis, 10 had 21 foetal losses (86% occurred during the second and third trimester) and 13 had deep vein thrombosis. Other clinical manifestations were thrombocytopaenia in six patients, livedo reticularis in four, anaemia in three, migraine in three and one with transient cerebral ischaemia. Four female patients had successful term pregnancies. Three patients had recurrent thrombosis (two with deep vein thrombosis and one pulmonary thromboembolism) despite anticoagulant treatment. The most frequent initial antiphospholipid syndrome manifestations were deep vein thrombosis (44.8%) and pregnancy loss (34.5%). During the 29 months follow-up (3-29 months, mean 14 months) no patients developed Systemic Lupus Erythematosus (SLE) or other autoimmune disease.